Literature DB >> 31951577

Severing Ties: Quantifying the Payload Release from Antibody Drug Conjugates.

Anna Kopp1, Greg M Thurber2.   

Abstract

As a key mediator of efficacy and toxicity, the linker connecting the payload in antibody drug conjugates determines cellular distribution and payload release. Sorkin et al. (2019) have created novel fluorescence-based linkers to quantify the rate of intracellular bond cleavage and track live-cell kinetics for designing more effective agents.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31951577      PMCID： PMC7297053          DOI： 10.1016/j.chembiol.2019.12.001

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN： 2451-9448            Impact factor:   8.116


  10 in total

1.  Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.

Authors:  Kevin J Hamblett; Peter D Senter; Dana F Chace; Michael M C Sun; Joel Lenox; Charles G Cerveny; Kim M Kissler; Starr X Bernhardt; Anastasia K Kopcha; Roger F Zabinski; Damon L Meyer; Joseph A Francisco
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

2.  Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.

Authors:  Andrew G Polson; Jill Calemine-Fenaux; Pamela Chan; Wesley Chang; Erin Christensen; Suzanna Clark; Frederic J de Sauvage; Dan Eaton; Kristi Elkins; J Michael Elliott; Gretchen Frantz; Reina N Fuji; Alane Gray; Kristin Harden; Gladys S Ingle; Noelyn M Kljavin; Hartmut Koeppen; Christopher Nelson; Saileta Prabhu; Helga Raab; Sarajane Ross; Dion S Slaga; Jean-Philippe Stephan; Suzie J Scales; Susan D Spencer; Richard Vandlen; Bernd Wranik; Shang-Fan Yu; Bing Zheng; Allen Ebens
Journal:  Cancer Res       Date:  2009-03-03       Impact factor: 12.701

3.  Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design.

Authors:  Katie F Maass; Chethana Kulkarni; Alison M Betts; K Dane Wittrup
Journal:  AAPS J       Date:  2016-02-24       Impact factor: 4.009

4.  An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.

Authors:  Steven R Leong; Wei-Ching Liang; Yan Wu; Lisa Crocker; Eric Cheng; Deepak Sampath; Rachana Ohri; Helga Raab; Philip E Hass; Thinh Pham; Ron Firestein; Dongwei Li; Melissa Schutten; Nicola J Stagg; Annie Ogasawara; Neelima Koppada; Leslie Roth; Simon P Williams; Byoung-Chul Lee; Cecile Chalouni; Ivan Peng; Jason DeVoss; Jarrod Tremayne; Paul Polakis; Andrew G Polson
Journal:  Mol Pharm       Date:  2015-04-23       Impact factor: 4.939

5.  Responsive Antibody Conjugates Enable Quantitative Determination of Intracellular Bond Degradation Rate.

Authors:  Michelle R Sorkin; Joshua A Walker; Sneha R Kabaria; Nicole P Torosian; Christopher A Alabi
Journal:  Cell Chem Biol       Date:  2019-10-08       Impact factor: 8.116

6.  Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.

Authors:  Hans K Erickson; Wayne C Widdison; Michele F Mayo; Kathleen Whiteman; Charlene Audette; Sharon D Wilhelm; Rajeeva Singh
Journal:  Bioconjug Chem       Date:  2010-01       Impact factor: 4.774

7.  SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm.

Authors:  Kevin J Hamblett; Allison P Jacob; Jesse L Gurgel; Mark E Tometsko; Brooke M Rock; Sonal K Patel; Robert R Milburn; Sophia Siu; Seamus P Ragan; Dan A Rock; Christopher J Borths; Jason W O'Neill; Wesley S Chang; Margaret F Weidner; Matthew M Bio; Kim C Quon; William C Fanslow
Journal:  Cancer Res       Date:  2015-12-02       Impact factor: 12.701

8.  Tracking Antibody Distribution with Near-Infrared Fluorescent Dyes: Impact of Dye Structure and Degree of Labeling on Plasma Clearance.

Authors:  Cornelius Cilliers; Ian Nessler; Nikolas Christodolu; Greg M Thurber
Journal:  Mol Pharm       Date:  2017-03-31       Impact factor: 4.939

9.  CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicity.

Authors:  C Kimberly Tsui; Robyn M Barfield; Curt R Fischer; David W Morgens; Amy Li; Benjamin A H Smith; Melissa Anne Gray; Carolyn R Bertozzi; David Rabuka; Michael C Bassik
Journal:  Nat Chem Biol       Date:  2019-08-26       Impact factor: 15.040

Review 10.  Trastuzumab emtansine: mechanisms of action and drug resistance.

Authors:  Mark Barok; Heikki Joensuu; Jorma Isola
Journal:  Breast Cancer Res       Date:  2014-03-05       Impact factor: 6.466
  10 in total
  4 in total

1.  Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice.

Authors:  Hsuan-Ping Chang; Zhe Li; Dhaval K Shah
Journal:  Pharm Res       Date:  2022-01-19       Impact factor: 4.200

Review 2.  Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.

Authors:  Rotimi Sheyi; Beatriz G de la Torre; Fernando Albericio
Journal:  Pharmaceutics       Date:  2022-02-11       Impact factor: 6.321

Review 3.  Peptide-Based Bioconjugates and Therapeutics for Targeted Anticancer Therapy.

Authors:  Seong-Bin Yang; Nipa Banik; Bomin Han; Dong-Nyeong Lee; Jooho Park
Journal:  Pharmaceutics       Date:  2022-06-29       Impact factor: 6.525

Review 4.  Peptide-Drug Conjugates with Different Linkers for Cancer Therapy.

Authors:  Mona Alas; Azam Saghaeidehkordi; Kamaljit Kaur
Journal:  J Med Chem       Date:  2020-12-31       Impact factor: 7.446
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.